Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 9/20 | 0.55 |
| ▸ | BCHE known ✓ | P06276 | 9/20 | 0.51 |
| ▸ | SCN4A known ✓ | P35499 | 2/20 | 0.47 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20597421 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL1373413 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL22500017 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL29414409 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL1373407 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL2148084 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| Hydrochloric Acid SCHEMBL1375746 | 1.00 | ACHE (0.55) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL1993388 | 0.98 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL14018259 | 0.98 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A | |
| SCHEMBL352022 | 0.98 | ACHE (0.57) | ACHEBCHEBACE1ALDH1A1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114835631-B | Preparation method of cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride | 重庆恩联生物科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-112213402-B | Method for detecting (3R, 4R) -1-benzyl-N, 4-dimethylpiperidine-3-amine dihydrochloride and isomer thereof | 江苏晶立信医药科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-114835631-A | Preparation method of cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride | 重庆恩联生物科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| CN-107056681-B | A kind of support method replaces the preparation method of cloth intermediate | 广州白云山光华制药股份有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-107056681-A | A kind of support method replaces the preparation method of cloth intermediate | 广州白云山光华制药股份有限公司 | 2017-08-18 | — | — | CN | claimed |
| CN-105153166-A | N- [ (3R,4R) -1-benzyl-4-methylpiperidin-3-yl ] -N-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-amine crystal | HUBEI LIVSCIEN PHARM SCI & TECH CO LTD | 2015-12-16 | — | — | CN | claimed |
| CN-114835631-B | Preparation method of cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride | 重庆恩联生物科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-114835631-B | Preparation method of cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride | 重庆恩联生物科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-114835631-B | Preparation method of cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride | 重庆恩联生物科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-113899831-B | Liquid chromatography detection method for tofacitinib citrate starting material | 湖北科益药业股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-112213402-B | Method for detecting (3R, 4R) -1-benzyl-N, 4-dimethylpiperidine-3-amine dihydrochloride and isomer thereof | 江苏晶立信医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-112213402-B | Method for detecting (3R, 4R) -1-benzyl-N, 4-dimethylpiperidine-3-amine dihydrochloride and isomer thereof | 江苏晶立信医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114835631-A | Preparation method of cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride | 重庆恩联生物科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-1666481-A2 | OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS | Pfizer Products Incorporated (US) | 2006-06-07 | — | — | EP | disclosed |
| CN-1729192-A | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors | PFIZER PROD INC (US) | 2006-02-01 | — | — | CN | disclosed |
| EP-1609781-A1 | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine | Pfizer Products Incorporated (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20040229923-A1 | Chiral salt resolution | PFIZER INC. | 2004-11-18 | — | — | US | disclosed |
| EP-1392694-A1 | OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030073719-A1 | Chiral salt resolution | PFIZER INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002096909-A1 | OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229923-A1 | Chiral salt resolution | REN, SRR, RER1 | ACHE 2037/4885BCHE 1926/4885SCN4A 362/4885 |
| US-20030073719-A1 | Chiral salt resolution | REN, SRR, RER1 | ACHE 2037/4885BCHE 1926/4885SCN4A 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.